 with
one stent. The mean lesion treated was 7.1 cm in stent
cohort and 6.4 cm in the angioplasty cohort. The reported
observed patency at 1 year was 81.3% and 36.7%, respectively, for the stent and angioplasty groups.194 In a 3year follow-up of the RESILIENT study, freedom from
target lesion revascularization and clinical success was
signiï¬cantly higher in the primary stent cohort, but no
data were available on patency.210
The Study for Evaluating Endovascular Treatments of
Lesions in the Superï¬cial Femoral Artery and Proximal
Popliteal By Using the Protege EverfLex Nitinol Stent System II (DURABILITY II) trial was a single-arm trial investigating the efï¬cacy of a single self-expanding nitinol stent in
the treatment of occlusive lesions in the SFA >4 and <
20 cm. Duplex-derived primary patency at 1 year was
77.2% for lesions with a mean length of 8.9 cm.211 The Zilver PTX trial randomly assigned 471 patients with SFA lesions averaging 6.5 cm to treatment with a paclitaxel DES
or PTA as a primary procedure and to BMS in a subset of
110 study patients who required further treatment for immediate failure of PTA alone. Patency at 1 year was 83.1%
for DES and 32.8% for PTA. In the 110 patients undergoing
salvage stenting for failed PTA, 1-year patency was signiï¬cantly better for DES compared with BMS (89.9% vs
73%).204 The patency superiority of paclitaxel DES over
PTA (74.8% vs 26.5%) and BMS (83.4% vs 64.1%) was sustained in a 2-year follow-up report of the same study.212
PTFE-covered self-expanding stents have been used to
treat long-segment lesions within the SFA for patients
with claudication, although their superiority to B